Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Overcoming carfilzomib resistance

David Simpson • 14 Sep 2019
IMW 2019
Multiple Myeloma Carfilzomib Ritonavir

David Simpson, MBChB, FRACP, FRCPA of North Shore Hospital, Auckland, New Zealand, explains the resistance mechanism of myeloma cells to carfilzomib, and describes the success of infusion with ritonavir in patients who have reduced response. Dr Simpson goes on to outline the need to assess the most efficient time for the administration of carfilzomib in myeloma patients in order to eliminate resistance-related cells. This interview was filmed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals